So far, 8,000 participants in different centers in Pune, Chennai, Kolkata, Delhi and Bhubaneswar have received the vaccine or a placebo, among other things as part of the process sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec.
Registration of approximately 10,500 participants in the phase III clinical study of the indigenous one-off Panacea Biotec developed Dengue vaccine, Dengiall, will probably be completed in October in 20 centers in India, according to ICMR scientists.
So far, 8,000 participants in different centers in Pune, Chennai, Kolkata, Delhi and Bhubaneswar have received the vaccine or a placebo, among other things as part of the process sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec.
The test is also read by ICMR-National Institute of Translational Virology and AIDS Research in Pune, National Institute of Epidemiology (NIE), Chennai and National Institute of Virology, Pune.
Currently there is no antiviral treatment or a recognized vaccine against docking fever in India.
The results of the phase-1/2 study have not shown safety problems for the One-shot vaccine, said NIE director Dr. Manoj Murhekar.
“The participants registered for the III study phase will be followed for two years. This study will evaluate the efficacy of this tetravalent dengue vaccine,” Dr. Murhekar.
The multi-center, double-blind, randomized, placebo-controlled phase-III study was launched in August last year to evaluate the efficacy, safety and long-term immunogenity of the JAB.
The first participant in this test was vaccinated last year at the Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak.
The development of an effective vaccine is complex because of the need to achieve good activity for all four serotypes. The Dengue virus has four serotypes, 1-4, with low cross protection against each other, which means that individuals can experience repeated infections, said Dr. Murhekar.
In India it is known that all four serotypes of the Dengue virus are circulating or co-circulating in many regions.
The Ministry of Health in a statement earlier had said that the tetravalent dengue vaccine (TV003/TV005), originally developed by the National Institutes of Health (NIH), has shown promising results in clinical tests in Brazil.
Panacea Biotec, one of the three Indian companies that receive the tribe, is in the most advanced development phase. The company has worked extensively on these tensions to develop a fully -fledged vacc information and has a processocent for this work.
Dengue is a major problem for public health in India and is in the top 30 countries with the highest incidence of the disease.
The worldwide incidence of Dengue has steadily increased over the past two decades, with more than 129 countries reporting dengue viral disease at the end of 2023, according to the World Health Organization (WHO).
In India, around 75-80 percent of the infections are asymptomatic, but these individuals can still transfer the infection by the bite of Aedes mosquitoes.
Of the 20-25 percent of the cases in which the symptoms are clinically clear, children run a considerably higher risk of hospitalization and mortality. In adults, the disease can escalate in severe conditions such as dengue hemorrhagic fever and dengue shock syndrome.
According to the government data, about 12,043 Dengue cases were reported until March of this year. In 2024, 2.3 Lakh fell and 297 deaths were registered.
Published on July 13, 2025
#Indias #dengue #vaccine #ICMR #complete #phase3 #clinical #test #registration #October